PT-141

Mechanism of Action

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, primarily MC3R and MC4R, located in the central nervous system. It is a metabolite of melanotan II, originally developed for its tanning properties.

Unlike phosphodiesterase type 5 inhibitors (e.g., sildenafil) that act on the vascular system, PT-141 works centrally through the melanocortin system. By activating MC4R in the hypothalamus, it modulates neural pathways involved in sexual arousal and desire.

The compound influences the release of dopamine in areas of the brain associated with sexual function, leading to increased sexual desire and arousal through a mechanism distinct from hormonal therapies.

Reported Effects

Commonly Reported

• Increased sexual desire in premenopausal women with HSDD (FDA-approved indication)
• Enhanced arousal through central nervous system pathways
• Efficacy independent of hormonal status
• Rapid onset of action (within minutes of subcutaneous injection)

Less Common Reports

• Potential benefits for male erectile dysfunction (pre-clinical data)
• Appetite suppression (related to melanocortin pathway)
• Skin darkening effects (melanocortin-mediated)
• Mood modulation effects

FDA-approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women.

Side Effects & Safety Profile

Low Concern

• Nausea (most common, ~40% of users)
• Flushing
• Headache
• Injection site reactions

Moderate Concern

• Vomiting (less common than nausea)
• Transient blood pressure elevation
• Potential for repeated dosing (limited to 8 doses per month)
• Fatigue

Serious

• Temporary blood pressure increase (monitoring recommended)
• Darkening of skin and gums (may be irreversible)
• Not recommended for patients with uncontrolled hypertension
• Contraindicated with PDE5 inhibitors due to blood pressure risk

PT-141 is an FDA-approved medication (Vyleesi). Consult a healthcare provider before use.

Clinical Evidence

• Phase III RECONNECT trials — Two pivotal trials demonstrating statistically significant improvement in sexual desire and reduction in distress related to low sexual desire in premenopausal women
• Phase II male ED trials — Some evidence of efficacy, though development focused on female HSDD
• Dose-response studies — Characterized optimal dosing (1.75mg subcutaneous) and timing
• Safety database — Over 1,200 subjects in clinical development program

FDA approved as Vyleesi (AMAG Pharmaceuticals/Palatin Technologies) in 2019.

Discovery Timeline

• 1960s — Alpha-melanocyte-stimulating hormone (α-MSH) characterized
• 1990s — Melanotan II developed; observed sexual side effects led to PT-141 development
• 2000s — PT-141 separated from melanotan II and studied independently
• 2007 — Initial FDA rejection (concerns about blood pressure effects)
• 2019 — FDA approves Vyleesi (bremelanotide) for HSDD in premenopausal women
• 2020–present — Marketed by AMAG Pharmaceuticals; expanded access discussions

Community Research Notes

The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.

"The erections I have gotten have been like being 15 again." — r/Peptides

"It is not just about the physical response, you actually want it." — r/Biohackers

"It took a long time to kick in, 6 to 8 hours or so. No real increase in libido but we decided to fool around out of boredom and sick of waiting. Then it hit." — r/Peptides

Frequently Asked Questions

Is PT-141 FDA approved? Yes. Bremelanotide (Vyleesi) was FDA approved in 2019 for hypoactive sexual desire disorder in premenopausal women. It is also used off-label for male sexual dysfunction.

How is PT-141 different from Viagra? Viagra works on blood vessels to enable erections. PT-141 works on the brain to create desire. They address different parts of the sexual response. Some people use both for a combined effect.

How long does PT-141 take to work? Onset is typically 4 to 6 hours after administration, with peak effects at 6 to 8 hours. Effects can last 24 to 72 hours. Planning ahead is important.

What are the side effects? The most common side effect is nausea, particularly at higher doses. Facial flushing, headache, and transient blood pressure changes are also reported. Starting with a lower dose helps assess tolerance.

Can women use PT-141? Yes. The FDA approval is specifically for women. The mechanism works the same way regardless of sex. It acts on the same melanocortin receptors in both men and women.

Compounds That Pair Well

• Kisspeptin — For a combined hormonal and neural approach to sexual health. Kisspeptin stimulates the reproductive hormone axis, PT-141 activates the neural arousal pathway. Complementary mechanisms.
• Ipamorelin — For GH support that may improve overall energy and vitality.
• BPC-157 — For general recovery and wellbeing while focusing on sexual health protocols.
• MOTS-c — For energy and endurance support that complements PT-141's effects.
• GHK-Cu — For general health and anti-aging support alongside targeted sexual health.

Build Your Personalised Protocol

PT-141 is one of many compounds available in the BioStack Generator. Explore hormonal and sexual health stacks alongside other compounds.

Get Your BioStack →